Advances in the Standard of Care in TNBC: Addressing Health Disparities and Integrating ADCs Into Treatment

Disclosure of Conflict of Interest
AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.

AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: Ricki Fairley, BA, MBA, reported a financial interest/relationship or affiliation in the form of Grant: Novartis Pharmaceuticals Corp; Genentech, Inc; Gilead; and Eisai Inc. Sara M. Tolaney, MD, MPH, reported a financial interest/relationship or affiliation in the form of Consultant/Advisory boards: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Merck & Co., Inc., Nektar Pharmaceuticals Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Bristol-Myers Squibb Company, Eisai Inc., and Nanostring. Consultant/Steering Committee: Eli Lilly and Company, Odonate, and CytomX. Advisory board: Genentech/Roche, Immunomedics/Gilead, Puma, Sanofi, Kyowa Kirin Pharmaceuticals, Samsung Bioepsis Inc., Certara, Mersana Therapeutics, Ellipses Pharma, 4D Pharma, OncoSec Medical Incorporated, Silverback Therapeutics, G1 Therapeutics, Celldex, Inc., and BeyondSpring Pharmaceuticals. Contracted research: Cyclacel, Seattle Genetics, Inc., and Exelixis, Inc. Consultant: Daiichi- Sankyo, Inc., Athenex, OncoPep, and Chugai Pharma USA, LLC. Steering Committee: OncXerna. Kristen Whitaker, MD, MS, reported a financial interest/relationship or affiliation in the form of Consultant: Novartis Pharmaceuticals Corp.

The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.